New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment

Frontiers in Pharmacology

Volumn 3 JUL, Issue , 2012, Pages

  Noël, Agnès ^a   Gutiérrez Fernández, Ana ^b   Sounni, Nor Eddine ^a   Behrendt, Niels ^c,d   Maquoi, Erik ^a   Lund, Ida K ^c,d   Cal, Santiago ^b   Hoyer Hansen, Gunilla ^c,d   López Otín, Carlos ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c FINSEN LABORATORY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

ADAM; Cancer; Matrix metalloproteinases; Microenvironment; Tumor

Indexed keywords

ADAM PROTEIN; ADAM29 PROTEIN; ADAM7 PROTEIN; ADAMTS1 PROTEIN; COLLAGENASE 3; HEMOPEXIN; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PHOSPHOTRANSFERASE INHIBITOR; TETRACYCLINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CYTOKINE RELEASE; EPIGENETICS; EXTRACELLULAR MATRIX; GENE MUTATION; GENE SILENCING; HUMAN; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84866143444     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00140     Document Type: Article

References (127)

1. Balbin, M.,Fueyo, A., Tester, A. M., Pen-das, A. M., Pitiot, A. S., Astudillo, A., Overall, C. M., Shapiro, S. D., and Lopez-Otin, C. (2003). Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet. 35,252-257.
2. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Ito-hara, S., Werb, Z., and Hanahan, D. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744.
3. Bundesmann, M. M., Wagner, T. E., Chow, Y. H., Altemeier, W. A., Stein-bach, T., and Schnapp, L. M. (2012). Role of urokinase plasminogen activator receptor-associated protein in mouse lung. Am. J. Respir. Cell Mol. Biol. 46, 233-239.
4. Cal, S., Obaya, A. J., Llamazares, M., Garabaya, C., Quesada, V., and Lopez-Otin, C. (2002). Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 283, 49-62.
5. Cauwe, B., and Opdenakker, G. (2010). Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 45, 351-423.
6. Cauwe, B., Van den Steen, P. E., and Opdenakker, G. (2007). The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 42,113-185.
7. Chabottaux, V., Ricaud, S., Host, L., Blacher, S., Paye, A., Thiry, M., Garo-falakis, A., Pestourie, C., Gombert, K., Bruyere, F., Lewandowsky, D., Tavitian, B., Foidart, J. M., Duconge, F., and Noel, A. (2009). Membrane-type 4 matrix metal-loproteinase (MT4-MMP) induces lung metastasis by alteration of primary breast tumour vascular architecture. J. Cell. Mol. Med. 13, 4002-4013.
8. Chabottaux, V., Sounni, N. E., Pen-nington, C. J., English, W. R., van den Brule, F., Blacher, S., Gilles, C., Munaut, C., Maquoi, E., Lopez-Otin, C., Murphy, G., Edwards, D. R., Foidart, J. M., and Noel, A. (2006). Membrane-type 4 matrix metallo-proteinase promotes breast cancer growth and metastases. Cancer Res. 66,5165-5172.
9. Chang, H. J., Yang, M. J., Yang, Y. H., Hou, M. F., Hsueh, E. J., and Lin, S. R. (2009). MMP13 is potentially a new tumor marker for breast cancer diagnosis. Oncol. Rep. 22, 1119-1127.
10. Chun, T. H., Sabeh, F., Ota, I., Murphy, H., McDonagh, K. T., Holmbeck, K., Birkedal-Hansen, H., Allen, E. D., and Weiss, S. J. (2004). MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix.J. Cell Biol. 167, 757-767.
11. Colige, A., Ruggiero, F., Vandenberghe, I., Dubail, J., Kesteloot, F., Van Beeumen, J., Beschin, A., Brys, L., Lapiere, C. M., and Nusgens, B. (2005). Domains and maturation processes that regulate the activity of ADAMTS-2, a metallopro-teinase cleaving the aminopropep-tide of fibrillar procollagens types I-III and V. J. Biol. Chem. 280, 34397-34408.
12. Collen, A., Hanemaaijer, R., Lupu, E, Quax, P. H., van Lent, N., Grimbergen, J., Peters, E., Kool-wijk, P., and van Hinsbergh, V. W (2003). Membrane-type matrix metalloproteinase-mediated angio-genesis in a fibrin-collagen matrix. Blood 101, 1810-1817.
13. Coussens, L. M., Fingleton, B. B., and Matrisian,L.M. (2002).Matrixmet-alloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392.
14. Coussens, L. M., and Werb, Z. (2001). Inflammatory cells and cancer: think different! J. Exp. Med. 193, F23-F26.
15. Curino, A. C., Engelholm, L. H., Yamada, S. S., Holmbeck, K., Lund, L. R., Molinolo, A. A., Behrendt, N., Nielsen, B. S., and Bugge, T. H. (2005). Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J. Cell Biol. 169, 977-985.
16. Decock, J., Hendrickx, W., Drijkonin-gen, M., Wildiers, H., Neven, P., Smeets, A.,and Paridaens,R. (2007). Matrix metalloproteinase expression patterns in luminal A type breast carcinomas. Dis. Markers 23, 189-196.
17. Decock, J., Thirkettle, S., Wagstaff, L., and Edwards, D. R. (2011). Matrix metalloproteinases: protective roles in cancer. J. Cell Mol. Med. 15,1254-1265
18. Deryugina, E. I., Soroceanu, L., and Strongin, A. Y. (2002). Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res. 62, 580-588
19. Detry, B., Bruyere, F., Erpicum, C., Pau-pert, J., Lamaye, F., Maillard, C., Lenoir, B., Foidart, J. M., Thiry, M., and Noel, A. (2011). Digging deeper into lymphatic vessel formation in vitro and in vivo. BMC Cell Biol. 12,29. doi:10.1186/1471-2121-12-29
20. Detry, B., Erpicum, C., Paupert, J., Blacher, S., Maillard, C., Bruyere, F., Pendeville, H., Remacle, T., Lambert, V., Balsat, C., Ormenese, S., Lamaye, F., Janssens, E., Moons, L., Cataldo, D., Kridelka, F., Carmeliet, P., Thiry, M., Foidart, J. M., Stru-man, I., and Noel, A. (2012). Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood 119, 5048-5056
21. Devel, L., Czarny, B., Beau, F., Geor-giadis, D., Stura, E., and Dive, V. (2010). Third generation of matrix metalloprotease inhibitors: gain in selectivity by targeting the depth of the S1' cavity. Biochimie 92, 1501-150
22. Devel, L., Rogakos, V., David, A., Makaritis, A., Beau, F., Cuniasse, P., Yiotakis, A., and Dive, V. (2006). Development of selective inhibitors and substrate of matrix metalloproteinase-12.J. Biol. Chem. 281,11152-11160
23. Devy, L., Huang, L., Naa, L., Yanaman-dra, N., Pieters, H., Frans, N., Chang, E., Tao, Q., Vanhove, M., Lejeune, A., van Gool, R., Sexton, D. J., Kuang, G., Rank, D., Hogan, S., Paz-many, C., Ma, Y. L., Schoonbroodt, S., Nixon, A. E., Ladner, R. C., Hoet, R., Henderikx, P., Tenhoor, C., Rabbani, S. A., Valentino, M. L., Wood, C. R., and Dransfield, D. T. (2009). Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angio-genesis. Cancer Res. 69, 1517-1526
24. Dubail, J., Kesteloot, F., Deroanne, C., Motte, P., Lambert, V., Rakic, J. M., Lapiere, C., Nusgens, B., and Col-ige, A. (2010). ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity. Cell. Mol. Life Sci. 67, 4213-4232
25. Egeblad, M., Shen, H. C., Behonick, D. J., Wilmes, L., Eichten, A., Korets, L. V., Kheradmand, F., Werb, Z., and Coussens, L. M. (2007). Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev. Dyn. 236, 1683-1693
26. Egeblad, M., and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2,161-174
27. Eisenach, P. A., Roghi, C., Fogarasi, M., Murphy, G., and English, W. R. (2010). MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src. J. Cell. Sci. 123,4182-4193
28. El Hour, M., Moncada-Pazos, A., Blacher, S., Masset, A., Cal, S., Berndt, S., Detilleux, J., Host, L., Obaya, A. J., Maillard, C., Foidart, J. M., Ectors, F., Noel, A., and Lopez-Otin, C. (2010). Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis. Oncogene 29,3025-3032
29. Ellsworth, R. E., Hooke, J. A., Shriver, C. D., and Ellsworth, D. L. (2009). Genomic heterogeneity of breast tumor pathogenesis. Clin. Med. Oncol. 3, 77-85
30. Engelholm, L. H., Ingvarsen, S., Jurgensen, H. J., Hillig, T., Madsen, D. H., Nielsen, B. S., and Behrendt, N. (2009). The collagen receptor uPARAP/Endo180. Front. Biosci. 14, 2103-2114
31. Engelholm, L. H., List, K., Netzel-Arnett, S., Cukierman, E., Mitola, D. J., Aaronson, H., Kjoller, L., Larsen, J. K., Yamada, K. M., Strickland, D. K., Holmbeck, K., Dano, K., Birkedal-Hansen, H., Behrendt, N., and Bugge, T. H. (2003). uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. J. Cell Biol. 160,1009-1015
32. Erler, J. T., Bennewith, K. L., Cox, T. R., Lang, G., Bird, D., Koong, A., Le, Q. T., and Giaccia, A. J. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15, 35-44
33. Erler, J. T., and Weaver, V. M. (2009). Three-dimensional context regulation of metastasis. Clin. Exp. Metastasis 26, 35-49
34. Fanjul-Fernandez, M., Folgueras, A. R., Cabrera, S., and Lopez-Otin, C. (2010). Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta 1803, 3-19
35. Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meteriss-ian, S., Omeroglu, A., Hallett, M., and Park, M. (2008). Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518-527.
36. Fingleton, B. (2003). Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin. Ther. Targets 7, 385-397.
37. Fingleton, B. (2007). Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. 13, 333-346.
38. Fingleton, B. (2008). MMPs as therapeutic targets-still a viable option? Semin. Cell Dev. Biol. 19, 61-68.
39. Fingleton, B., and Lynch, C. C. (2010). A new dress code for MMPs: cleavage optional. Dev. Cell 18,3-4.
40. Folgueras, A. R., Pendas, A. M., Sanchez, L. M., and Lopez-Otin, C. (2004). Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. 48,411-424.
41. Freije, J. M., Diez-Itza, I., Balbin, M., Sanchez, L. M., Blasco, R., Tolivia, J., and Lopez-Otin, C. (1994). Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 269, 16766-16773.
42. Gupta, G. P., Perk, J., Acharyya, S., de Candia, P., Mittal, V., Todorova-Manova, K., Gerald, W L., Brogi, E., Benezra, R., and Massague, J. (2007). ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc. Natl. Acad. Sci. U.S.A. 104, 19506-19511.
43. Gutierrez-Fernandez, A., Fueyo, A., Folgueras, A. R., Garabaya, C., Pen-nington, C. J., Pilgrim, S., Edwards, D. R., Holliday, D. L., Jones, J. L., Span, P. N., Sweep, F. C., Puente, X. S., and Lopez-Otin, C. (2008). Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res. 68, 2755-2763.
44. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
45. Handsley, M. M., and Edwards, D. R. (2005). Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer 115, 849-860.
46. Hasebe, T., Sasaki, S., Imoto, S., Mukai, K., Yokose, T., and Ochiai, A. (2002). Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod. Pathol. 15, 502-516.
47. Hawinkels, L. J., Kuiper, P., Wiercinska, E., Verspaget, H. W., Liu, Z., Pardali, E.,Sier,C.F.,and ten Dijke,P. (2010). Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res. 70,4141-4150.
48. Holmbeck, K., Bianco, P., and Birkedal-Hansen, B. (2003). MT1-MMP: a collagenase essential for tumor cell invasive growth. Cancer Cell. 81-84.
49. Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S. A., Mankani, M., Robey, P. G., Poole, A. R., Pidoux, I., Ward, J. M., and Birkedal-Hansen, H. (1999). MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99,81-92.
50. Host, L., Paye, A., Detry, B., Blacher, S., Munaut, C., Foidart, J. M., Seiki, M., Sounni, N. E., and Noel, A. (2012). The proteolytic activity of MT4-MMP is required for its proan-giogenic and pro-metastatic promoting effects. Int. J. Cancer. doi: 10.1002/ijc.27436
51. Hotary, K. B., Allen, E. D., Brooks, P. C., Datta, N. S., Long, M. W., and Weiss, S. J. (2003). Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114,33-45.
52. Hu, J., Van den Steen, P. E., Sang, Q. X., and Opdenakker, G. (2007). Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6, 480-498.
53. Hua, H., Li, M., Luo, T., Yin, Y., and Jiang, Y. (2011). Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell. Mol. Life Sci. 68, 3853-3868.
54. Hubmacher, D., and Apte, S. S. (2011). Genetic and functional linkage between ADAMTS superfam-ily proteins and fibrillin-1: a novel mechanism influencing microfibril assembly and function. Cell. Mol. Life Sci. 68, 3137-3148.
55. Joyce, J. A., and Pollard, J. W (2009). Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239-252.
56. Kajita, M., Itoh, Y., Chiba, T., Mori, H., Okada, A., Kinoh, H., and Seiki, M. (2001). Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol. 153, 893-904.
57. Kalluri, R. (2003). Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3, 422-433.
58. Kalluri, R., and Zeisberg, M. (2006). Fibroblasts in cancer. Nat. Rev. Cancer 6, 392-401.
59. Kessenbrock, K., Plaks, V., and Werb, Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67.
60. Kjoller, L., Engelholm, L. H., Hoyer-Hansen, M., Dano, K., Bugge, T. H., and Behrendt, N. (2004). uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV. Exp. Cell Res. 293,106-116.
61. Kleifeld, O., Kotra, L. P., Gervasi, D. C., Brown, S., Bernardo, M. M., Frid-man, R., Mobashery, S., and Sagi, I. (2001). X-Ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to ahighly selective mechanism-based inhibitor. Comparison with the latent and active forms of the enzyme. J. Biol. Chem. 276,17125-17131.
62. Klein, T., and Bischoff, R. (2011). Active metalloproteases of the A disintegrin and metalloprotease (ADAM) family: biological function and structure.J. Proteome Res. 10, 17-33.
63. Kogianni, G., Walker, M. M., Waxman, J., and Sturge, J. (2009). Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression. Eur. J. Cancer 45, 685-693
64. Korpi, J. T., Kervinen, V., Maklin, H., Vaananen, A., Lahtinen, M., Laara, E., Ristimaki, A., Thomas, G., Yli-palosaari, M., Astrom, P., Lopez-Otin, C., Sorsa, T., Kantola, S., Pirila, E., and Salo,T. (2008). Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Br. J. Cancer 98, 766-775.
65. Kruger, A., Kates, R. E., and Edwards, D. R. (2010). Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim. Biophys. Acta 1803,95-102.
66. Langlois, S., Gingras, D., and Beliv-eau, R. (2004). Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood 103, 3020-3028.
67. Lederle, W., Hartenstein, B., Meides, A., Kunzelmann, H., Werb, Z., Angel, P., and Mueller, M. M. (2009). MMP 13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis 31,1175-1184.
68. Lee, C. F., Ling, Z. Q., Zhao, T., Fang, S. H., Chang, W.C., Lee, S. C., and Lee, K. R. (2009). Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma. World J. Gastroenterol. 15, 356-365.
69. Lee, N. V., Sato, M., Annis, D. S., Loo, J. A.,Wu, L., Mosher, D. F., and Iruela-Arispe, M. L. (2006). ADAMTS1 mediates the release of antiangio-genic polypeptides from TSP1 and 2. EMBOJ. 25, 5270-5283.
70. Llamazares, M., Obaya, A. J., Moncada-Pazos, A., Heljasvaara, R., Espada, J., Lopez-Otin, C., and Cal, S. (2007). The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway. J. Cell. Sci. 120, 3544-3552.
71. Lopez-Guisa, J. M., Cai, X., Collins, S. J., Yamaguchi, I., Okamura, D. M., Bugge, T. H., Isacke, C. M., Emson, C. L., Turner, S. M., Shank-land, S. J., and Eddy, A. A. (2012). Mannose receptor 2 attenuates renal fibrosis. J. Am. Soc. Nephrol. 23, 236-251.
72. Lopez-Otin, C., and Hunter, T. (2010). The regulatory crosstalk between kinases and proteases in cancer. Nat. Rev. Cancer 10,278-292.
73. Lopez-Otin, C., and Matrisian, L. M. (2007). Tumour microenvironment: emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 7, 800-808.
74. Lopez-Otin, C., and Overall, C. M. (2002). Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. CellBiol. 3,509-519.
75. Lopez-Otin, C., Palavalli, L. H., and Samuels, Y. (2009). Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle 8, 3657-3662.
76. Lu, P., Weaver, V. M., and Werb, Z. (2012). The extracellular matrix: a dynamic niche in cancer progression.J. CellBiol. 196,395-406.
77. Madsen, D. H., Engelholm, L. H.,Ingvarsen, S., Hillig, T., Wagenaar-Miller, R. A., Kjoller, L., Gardsvoll,H., Hoyer-Hansen, G., Holmbeck,K., Bugge, T. H., and Behrendt,N. (2007). Extracellular col-lagenases and the endocyticreceptor, urokinase plasmino-gen activator receptor-associatedprotein/Endo180, cooperate infibroblast-mediated collagen degradation. J. Biol. Chem. 282, 27037-27045.
78. Madsen, D. H., Ingvarsen, S., Jurgensen, H. J., Melander, M. C., Kjoller, L., Moyer, A., Honore, C., Madsen, C. A., Garred, P., Burgdorf, S., Bugge, T. H., Behrendt, N., and Engelholm, L. H. (2011). The non-phagocytic route of collagen uptake: a distinct degradation pathway. J. Biol. Chem. 286,26996-27010.
79. Madsen, D. H., Jurgensen, H. J., Ingvarsen, S., Melander, M. C., Vainer, B., Egerod, K. L., Hald, A., Rono, B., Madsen, C. A., Bugge, T. H., Engelholm, L. H., and Behrendt, N. (2012). Endocytic collagen degradation: a novel mechanism involved in protection against liver fibrosis. J. Pathol. 227, 94-105.
80. Maquoi, E., Assent, D., Detilleux, J., Pequeux, C., Foidart, J. M., and Noel, A. (2012). MT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis. Oncogene 31, 480-493.
81. Messaritou, G., East, L., Roghi, C., Isacke, C. M., and Yarwood, H. (2009). Membrane type-1 matrix metalloproteinase activity is regulated by the endocytic collagen receptor Endo180. J. Cell. Sci. 122, 4042-4048.
82. Mimura, T., Han, K. Y., Onguchi, T., Chang, J. H., Kim, T. I., Kojima, T., Zhou, Z., and Azar, D. T. (2009). MT1-MMP-mediated cleavage of decorin in corneal angiogenesis. J. Vasc. Res. 46, 541-550.
83. Minn, A. J., Gupta, G. P., Padua, D., Bos, P., Nguyen, D. X., Nuyten, D., Kreike, B., Zhang, Y., Wang, Y., Ishwaran, H., Foekens, J. A., van de Vijver, M., and Massague, J. (2007). Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Natl. Acad. Sci. U.S.A. 104, 6740-6745.
84. Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D.,Viale, A., Olshen, A. B., Gerald, W L., and Massague, J. (2005). Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524.
85. Moncada-Pazos, A., Obaya, A. J., Fraga, M. F., Viloria, C. G., Capella, G., Gausachs, M., Esteller, M., Lopez-Otin, C., and Cal, S. (2009). The ADAMTS12 metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer. J. Cell. Sci. 122, 2906-2913.
86. Montel, V., Kleeman, J., Agarwal, D., Spinella, D., Kawai, K., and Tarin, D. (2004). Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res. 64, 1687-1694.
87. Nguyen, D. X., and Massague, J. (2007). Genetic determinants of cancer metastasis. Nat. Rev. Genet. 8, 341-352.
88. Nielsen, B. S., Egeblad, M., Rank, F., Askautrud, H. A., Pennington, C. J., Pedersen, T. X., Christensen, I. J., Edwards, D. R., Werb, Z., and Lund, L. R. (2008). Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression. PLoS ONE 3, e2959. doi:10.1371/journal.pone.0002959
89. Nielsen, B. S., Rank, F., Illemann, M., Lund, L. R., and Dano, K. (2007). Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int. J. Cancer 120, 2086-2095.
90. Nielsen, B. S., Rank, F., Lopez, J. M., Balbin, M., Vizoso, F., Lund, L. R., Dano, K., and Lopez-Otin, C. (2001). Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res. 61, 7091-7100.
91. Noel, A., Jost, M., and Maquoi, E. (2008). Matrix metalloproteinases at cancer tumor-host interface. Semin. Cell Dev. Biol. 19,52-60.
92. Overall, C. M., and Kleifeld, O. (2006).Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227-239.
93. Overall, C. M., and Lopez-Otin, C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2, 657-672.
94. Page-McCaw, A., Ewald, A. J., and Werb,Z. (2007). Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. CellBiol. 8,221-233.
95. Palavalli, L. H., Prickett, T. D., Wun-derlich, J. R., Wei, X., Burrell, A. S., Porter-Gill, P., Davis, S., Wang, C., Cronin, J. C., Agrawal, N. S., Lin, J. C., Westbroek, W., Hoogstraten-Miller, S., Molinolo, A. A., Fetsch, P., Filie, A. C., O'Connell, M. P., Banister, C. E., Howard, J. D., Buckhaults, P., Weeraratna, A. T., Brody, L. C., Rosenberg, S. A., and Samuels, Y. (2009). Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat. Genet. 41,518-520.
96. Poincloux, R., Lizarraga, F., and Chavrier, P. (2009). Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J. Cell. Sci. 122,3015-3024.
97. Ramaswamy, S., Ross, K. N., Lander, E. S., and Golub, T. R. (2003). A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33, 49-54.
98. Remacle, A. G., Golubkov, V. S., Shiryaev, S. A., Dahl, R., Steb-bins, J. L., Chernov, A. V., Cheltsov, A. V., Pellecchia, M., and Stron-gin, A. Y. (2012). Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res. 72, 2339-2349.
99. Rocks, N., Paulissen, G., El Hour, M., Quesada, F., Crahay, C., Gueders, M., Foidart, J. M., Noel, A., and Cataldo, D. (2008). Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 90, 369-379.
100. Rodriguez, D., Morrison, C. J., and Overall, C. M. (2010). Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta 1803, 39-54.
101. Rodriguez-Manzaneque, J. C., Carpizo, D., Plaza-Calonge Mdel, C., Torres-Collado, A. X., Thai, S. N., Simons, M., Horowitz, A., and Iruela-Arispe, M. L. (2009). Cleavage of syndecan-4 by ADAMTS 1 provokes defects in adhesion. Int. J. Biochem. Cell Biol. 41,800-810.
102. Sabeh, F., Li, X. Y., Saunders, T. L., Rowe, R. G., and Weiss, S. J (2009). Secreted versus membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion. J. Biol. Chem. 284, 23001-23011
103. Schelter, F., Grandl, M., Seubert, B., Schaten, S., Hauser, S., Gerg, M., Boccaccio, C., Comoglio, P., and Kruger, A. (2011a). Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin. Exp. Metastasis 28, 793-802.
104. Schelter, F., Halbgewachs, B., Baumler, P., Neu, C., Gorlach, A., Schrotzl-mair,F.,and Kruger, A. (2011b). Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1alpha. Clin. Exp. Metastasis 28,91-99.
105. Sela-Passwell, N., Kikkeri, R., Dym, O., Rozenberg, H., Margalit, R., Arad-Yellin, R., Eisenstein, M., Brenner, O., Shoham, T., Danon, T., Shanzer, A., and Sagi, I. (2012). Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat. Med. 18, 143-147.
106. Sohail, A., Sun, Q., Zhao, H., Bernardo, M. M., Cho, J. A., and Fridman, R. (2008). MT4-(MMP17) and MT6-MMP (MMP25), a unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer. Cancer Metastasis Rev. 27,289-302.
107. Sounni, N. E., Dehne, K., van Kempen, L., Egeblad, M., Affara, N. I., Cuevas, I., Wiesen, J., Junankar, S., Korets, L., Lee, J., Shen, J., Morrison, C. J., Overall, C. M., Krane, S. M., Werb, Z., Boudreau, N., and Coussens, L. M. (2010a). Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech. 3, 317-332.
108. Sounni, N. E., Rozanov, D. V., Remacle, A. G., Golubkov, V. S., Noel, A., and Strongin, A. Y. (2010b). Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. Int. J. Cancer 126,1067-1078.
109. Sounni, N. E., Devy, L., Hajitou, A., Frankenne, F., Munaut, C., Gilles, C., Deroanne, C., Thompson, E. W., Foidart, J. M., and Noel, A. (2002). MT1-MMP expression promotes tumor growth and angiogen-esis through an up-regulation of vascular endothelial growth factor expression. FASEB J. 16,555-564.
110. Sounni, N. E., and Noel, A. (2005). Membrane type-matrix metalloproteinases and tumor progression. Biochimie 87, 329-342.
111. Sounni, N. E., Paye, A., Host, L., and Noël, A. (2011). MT-MMPs as regulators of vessel stability associated with angiogene-sis. Front. Pharmacol. 2:111. doi:10.3389/fphar.2011.00111
112. Sounni, N. E., Roghi, C., Chabot-taux, V., Janssen, M., Munaut, C., Maquoi, E., Galvez, B. G., Gilles, C., Frankenne, F., Murphy, G., Foidart, J. M., and Noel, A. (2004). Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metallo-proteinase through activation of Src-tyrosine kinases. J. Biol. Chem. 279, 13564-13574.
113. Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., and Marini, F. (2009). Mesenchymal stem cell transition to tumor-associated fibrob-lasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 4, e4992. doi:10.1371/journal.pone.0004992
114. Stratman, A. N., Saunders, W. B., Sacharidou, A., Koh, W., Fisher, K. E., Zawieja, D. C., Davis, M. J., and Davis, G. E. (2009). Endothelial cell lumen and vascular guidance tunnel formation requires MT1-MMP-dependent proteolysis in 3-dimensional collagen matrices. Blood 114,237-247.
115. Strongin, A. Y. (2010). Proteolytic and non-proteolytic roles of membrane type-1 matrix met-alloproteinase in malignancy. Biochim. Biophys. Acta 1803, 133-141.
116. Sulek, J., Wagenaar-Miller, R. A., Shire-man, J., Molinolo, A., Madsen, D. H., Engelholm, L. H., Behrendt, N., and Bugge, T. H. (2007). Increased expression of the collagen internal-ization receptor uPARAP/Endo180 in the stroma of head and neck cancer. J. Histochem. Cytochem. 55, 347-353.
117. Tatti, O., Vehvilainen, P., Lehti, K., and Keski-Oja, J. (2008). MT1-MMP releases latent TGF-beta1 from endothelial cell extracellular matrix via proteolytic processing of LTBP-1. Exp. Cell Res. 314, 2501-2514.
118. Tavazoie, S. F., Alarcon, C., Oskars-son, T., Padua, D., Wang, Q., Bos, P. D., Gerald, W. L., and Massague, J. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152.
119. Vagima, Y., Avigdor, A., Goichberg, P., Shivtiel, S., Tesio, M., Kalinkovich, A., Golan, K., Dar, A., Kollet, O., Petit, I., Perl, O., Rosenthal, E., Resnick, I., Hardan, I., Gellman, Y. N., Naor, D., Nagler, A., and Lapidot, T. (2009). MT1-MMP andRECKare involved in human CD34+ progenitor cell retention, egress, and mobilization. J. Clin. Invest. 119, 492-503.
120. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. H. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415,530-536.
121. Viloria, C. G., Obaya, A. J., Moncada-Pazos, A., Llamazares, M., Astudillo, A., Capella, G., Cal, S., and Lopez-Otin, C. (2009). Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. Cancer Res. 69, 4926-4934.
122. Vihinen, P., Ala-aho, R., and Kahari, V. M. (2005). Matrix metalloproteinases as therapeutic targets in cancer. Curr. Cancer Drug Targets 5, 203-220.
123. Wei, X., Prickett, T. D., Viloria, C. G., Molinolo, A., Lin, J. C., Cardenas-Navia, I., Cruz, P., Rosenberg, S. A., Davies, M. A., Gershenwald, J. E., Lopez-Otin, C., and Samuels, Y. (2010). Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol. Cancer Res. 8, 1513-1525.
124. Zhou, Z., Apte, S. S., Soininen, R., Cao, R., Baaklini, G. Y., Rauser, R. W., Wang, J., Cao, Y., and Tryg-gvason, K. (2000). Impaired endo-chondral ossification and angiogen-esis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. U.S.A. 97, 4052-4057.
125. Zigrino, P., Kuhn, I., Bauerle, T., Zamek, J., Fox, J. W., Neumann, S., Licht, A., Schorpp-Kistner, M., Angel, P., and Mauch, C. (2009). Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J. Invest. Dermatol. 129, 2686-2693.
126. Zucker, S., and Cao, J. (2009). Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time? Cancer Biol. Ther. 8, 2371-2373.
127. Zucker, S., Pei, D., Cao, J., and Lopez-Otin, C. (2003). Membrane type-matrix metalloproteinases (MT-MMP). Curr. Top. Dev. Biol. 54, 1-74.